Radiopharm Theranostics (RADX) Competitors $4.14 -0.06 (-1.43%) As of 07/11/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsOwnershipSEC FilingsTrendsBuy This Stock RADX vs. GNLX, SEER, NKTX, SKYE, ACTU, BHST, SGMO, OBIO, TNYA, and HURAShould you be buying Radiopharm Theranostics stock or one of its competitors? The main competitors of Radiopharm Theranostics include Genelux (GNLX), Seer (SEER), Nkarta (NKTX), Skye Bioscience (SKYE), Actuate Therapeutics (ACTU), BioHarvest Sciences (BHST), Sangamo Therapeutics (SGMO), Orchestra BioMed (OBIO), Tenaya Therapeutics (TNYA), and TuHURA Biosciences (HURA). These companies are all part of the "med - biomed/gene" industry. Radiopharm Theranostics vs. Its Competitors Genelux Seer Nkarta Skye Bioscience Actuate Therapeutics BioHarvest Sciences Sangamo Therapeutics Orchestra BioMed Tenaya Therapeutics TuHURA Biosciences Genelux (NASDAQ:GNLX) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends. Does the media prefer GNLX or RADX? In the previous week, Genelux had 3 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 4 mentions for Genelux and 1 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 1.89 beat Genelux's score of 0.97 indicating that Radiopharm Theranostics is being referred to more favorably in the news media. Company Overall Sentiment Genelux Positive Radiopharm Theranostics Very Positive Do analysts rate GNLX or RADX? Genelux currently has a consensus price target of $17.75, suggesting a potential upside of 417.49%. Radiopharm Theranostics has a consensus price target of $12.00, suggesting a potential upside of 189.86%. Given Genelux's higher probable upside, equities analysts clearly believe Genelux is more favorable than Radiopharm Theranostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Radiopharm Theranostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has higher earnings and valuation, GNLX or RADX? Radiopharm Theranostics has lower revenue, but higher earnings than Genelux. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenelux$10K12,944.82-$29.87M-$0.88-3.90Radiopharm TheranosticsN/AN/AN/AN/AN/A Is GNLX or RADX more profitable? Radiopharm Theranostics' return on equity of 0.00% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets GeneluxN/A -93.04% -74.17% Radiopharm Theranostics N/A N/A N/A Do institutionals & insiders believe in GNLX or RADX? 37.3% of Genelux shares are held by institutional investors. 9.3% of Genelux shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryGenelux beats Radiopharm Theranostics on 6 of the 10 factors compared between the two stocks. Get Radiopharm Theranostics News Delivered to You Automatically Sign up to receive the latest news and ratings for RADX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RADX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RADX vs. The Competition Export to ExcelMetricRadiopharm TheranosticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.11M$2.97B$5.62B$9.10BDividend YieldN/A2.39%5.24%4.00%P/E RatioN/A20.5828.0520.27Price / SalesN/A292.05429.5999.27Price / CashN/A42.8637.4658.16Price / BookN/A7.638.055.49Net IncomeN/A-$55.05M$3.18B$250.45M7 Day Performance4.02%8.43%3.60%4.77%1 Month Performance-22.33%5.42%4.03%7.66%1 Year PerformanceN/A2.03%29.49%16.39% Radiopharm Theranostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RADXRadiopharm TheranosticsN/A$4.14-1.4%$12.00+189.9%N/A$33.11MN/A0.00N/APositive NewsGap DownGNLXGenelux1.2695 of 5 stars$3.44-0.6%$17.75+416.0%+34.5%$129.83M$10K-3.9110News CoverageAnalyst UpgradeSEERSeer2.2437 of 5 stars$2.19+0.9%$3.00+37.0%+14.7%$128.92M$15.06M-1.55160NKTXNkarta1.8061 of 5 stars$1.80-0.6%$14.33+696.3%-71.7%$127.72MN/A-1.19140News CoverageSKYESkye Bioscience2.3106 of 5 stars$3.94-6.6%$16.60+321.3%-38.9%$122.06MN/A-4.8011High Trading VolumeACTUActuate Therapeutics2.7452 of 5 stars$6.18-6.5%$20.50+231.7%N/A$121.25MN/A0.0010Positive NewsBHSTBioHarvest SciencesN/A$7.22-1.5%$13.67+89.3%N/A$118.55M$25.19M-14.44N/APositive NewsSGMOSangamo Therapeutics2.7183 of 5 stars$0.50-5.0%$4.50+800.0%+12.2%$116.58M$63.76M-1.28480OBIOOrchestra BioMed2.9576 of 5 stars$3.00+0.7%$14.20+373.3%-63.4%$114.94M$2.89M-1.694News CoverageTNYATenaya Therapeutics3.6019 of 5 stars$0.69+2.5%$6.25+808.7%-80.5%$111.88MN/A-0.59110HURATuHURA Biosciences1.3247 of 5 stars$2.52+1.2%$12.67+402.6%N/A$110.07MN/A0.00N/A Related Companies and Tools Related Companies GNLX Competitors SEER Competitors NKTX Competitors SKYE Competitors ACTU Competitors BHST Competitors SGMO Competitors OBIO Competitors TNYA Competitors HURA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RADX) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Radiopharm Theranostics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Radiopharm Theranostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RADX Stock Alerts